Omar Shaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Omar Shaker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Mark Messak
Faculty of Medicine, Helwan University, Helwan, Egypt
2 shared publications Abdelrahman Shata
1 shared publicationAbdullah Almarfadi
1 shared publication- Ahmed Abdelmageed
Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication - Ahmed Negida
Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA
1 shared publication Asmaa Zakria Alnajjar
1 shared publication
Latest Publications
- 30 May 2026
- Published by Taylor & Francis in Neurodegenerative Disease Management
- p. 1-16
Bright light therapy for depression and excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression
Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD. PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed. Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent. BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.
- 30 May 2026
- Published by Taylor & Francis in Neurodegenerative Disease Management
- p. 1-16
Bright light therapy for depression and excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression
Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD. PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed. Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent. BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.